Neurol. praxi. 2024;25(2):88-89

Markery demence

prof. MUDr. Irena Rektorová, Ph.D., editorka hlavního tématu
1. neurologická klinika LF MU ve FN u sv. Anny a CEITEC, Masarykova univerzita, Brno

Published: April 16, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rektorová I, tématu EH. Markery demence. Neurol. praxi. 2024;25(2):88-89.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal α­‑synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23(2):178-190. doi: 10.1016/S1474-4422(23)00405-2. Go to original source... Go to PubMed...
    2. Höglinger GU, Adler CH, Berg D, et al. A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 2024;23(2):191-204. doi: 10.1016/S1474-4422(23)00404-0. Go to original source... Go to PubMed...
    3. Jack CR Jr, Bennett DA, Blennow K, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539-47. doi: 10.1212/WNL.0000000000002923. Go to original source... Go to PubMed...
    4. Nemergut M, Marques SM, Uhrik L, et al. Domino­‑like effect of C112R mutation on ApoE4 aggregation and its reduction by Alzheimer's Disease drug candidate. Mol Neurodegener. 2023;18(1):38. doi: 10.1186/s13024-023-00620-9. Go to original source... Go to PubMed...
    5. Morris HR. Autosomal dominant Parkinson's disease and the route to new therapies. Expert Rev Neurother. 2007;7(6):649-56. doi: 10.1586/14737175. 7. 6.649. Go to original source...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.